No Data
Express News | Guangzhou Baiyunshan Pharmaceutical - Received Written Resignation From Wu Changhai as Executive Director
Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License
The subsidiary of BAIYUNSHAN PH (00874.HK) has reduced the production line at He Jigong Pharmaceutical Factory.
On February 12, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that recently, its subsidiary Guangzhou BAIYUNSHAN Pharmaceutical Group Co., Ltd. Huo Jigong Pharmaceutical Factory (hereinafter referred to as "Huo Jigong Pharmaceutical Factory") received the "Pharmaceutical Production License" approved and issued by the Guangdong Provincial Pharmaceutical Administration, allowing Huo Jigong Pharmaceutical Factory to reduce its production lines. The changes to the copy of the Pharmaceutical Production License are as follows: Huo Jigong Pharmaceutical Factory is authorized to reduce the production line in the workshop "Xingzhou Manufacturing Department" located at the production address "No. 4, South Chuangye Avenue, Mingzhu Industrial Park, Conghua City, Guangzhou (except Building K1)" for the production line "F Building." The production scope of the F Building production line.
BAIYUNSHAN PH (00874) has completed the change of its legal representative and obtained a new business license.
BAIYUNSHAN PH (00874) issued an announcement, Guangzhou BAIYUNSHAN PH Pharmaceutical Group Co., Ltd. ("the company") in 2025...
Earnings Working Against Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Share Price
Guangzhou Baiyunshan Pharmaceutical Passes Generic Drug Evaluation for Antibiotic Drug
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
